FLORHAM PARK, N.J., Dec. 1, 2020 /PRNewswire/ — Celularity announced today that the independent Data Monitoring Committee (DMC) completed...
Celularity announced today that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial. The patient was treated at UC Irvine in California, the first CA site to open for patient enrollment with support from a COVID-19 Project grant awarded to Celularity by the California Institute for Regenerative Medicine (CIRM). Participating trial sites include Hackensack University Medical Center and Atlantic Health in New Jersey, MultiCare Health System in Washington State, Banner University Medical Center Phoenix in Arizona, the University of Arkansas in Arkansas, and UC Davis in California. The Principal Investigator is Corey Casper, M.D., MPH, of the Infectious Disease Research Institute (IDRI) ClinicalTrials.gov Identifier: NCT04365101.
Celularity, Inc. (”Celularity” or “the Company”) today announced that it has sold its UltraMIST® Ultrasound...
University of California Irvine is the first California site participating in Celularity’s CYNK-001-COVID-19 clinical trial...
The expanded strategic collaboration includes the use of Celularity's proprietary CYNK-001 for treatment of SARS-CoV-2 virus, which causes COVID-19 and Acute Respiratory Distress Syndrome
CYNK-001, the company's allogeneic, off-the-shelf, cryopreserved Natural Killer cell therapy to be used in Phase I/II study
Dr. Robert Hariri, CEO and founder of Celularity, discusses how the company is exploring a...
The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults...
WARREN, N.J.–(BUSINESS WIRE)–Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage company developing allogeneic cellular therapies...
WARREN, N.J.–(BUSINESS WIRE)–Celularity, Inc. (“Celularity”), a clinical-stage cell therapeutics company focused on the development of...